ArticleBMC neuroscience2025
Guanidino compounds with native GABA(A) δ receptor selectivity: a tale of homeostatic compensation in δ-KO mice.
Article in BMC neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Altered GABAergic transmission has been implicated in the neurological symptoms of metabolic disorders associated with guanidino compound (GC) accumulation. Building on previous findings that selected GCs act as direct orthosteric GABAA receptor (GABAR) agonists, we now asked whether these GCs act preferentially on high-affinity extrasynaptic δ subunit-containing receptors (δ-GABAs). Using whole-cell patch clamp recordings from mouse cerebellar granule cells (CGCs) in brain slices of wild-type and δ-subunit knockout (δ-KO) mice, together with 5 nM [³H]muscimol displacement assays on WT and δ-KO forebrains, we compared the actions of four structurally GABA-like GCs — guanidinoacetate (GAA), β-guanidinopropionate (β-GPA), guanidinoethanesulfonate (GES), and γ-guanidinobutyrate (γ-GBA). These compounds activated CGC GABARs in cumulative concentration-response curves and displaced the highly δ-GABAR-selective ligand [3H]muscimol suggesting δ-GABAR-selective orthosteric agonist actions. In δ-KO forebrains, total [³H]muscimol binding was reduced by ~ 50%, confirming the loss high-agonist-affinity but low-abundance (~ 5% of total forebrain GABARs) δ-GABARs. δ-KO CGCs showed markedly reduced agonist sensitivity, with EC₅₀ values (µM, WT/δ-KO): GABA (2/6) < β-GPA (3/8) < GAA (4/14) < GES (32/72) < γ-GBA (44/219). The modest loss of agonist sensitivity for GABA and the four GABA-mimetic GCs in δ-KO CGCs is consistent with compensatory upregulation of non-δ extrasynaptic GABARs containing only α and β subunits, as previously described (Tretter et al., JBC 2001), explaining the preserved tonic inhibition in δ-KO neurons. Our findings demonstrate that GABA-mimetic GCs preferentially target δ-GABARs and suggest that homeostatic compensation by αβ-type GABARs is a key adaptive mechanism maintaining inhibitory tone in δ-KO CGC neurons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.